Last 7 days
-4.9%
Last 30 days
21.0%
Last 90 days
16.7%
Trailing 12 Months
91.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 304.8B | 1.4B | -3.73% | 61.04% | -152.12 | 215.28 | 20.37% | -37.45% |
ABBV | 275.0B | 58.1B | 0.21% | 1.63% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 80.1B | 12.2B | -0.48% | 14.17% | 18.47 | 6.58 | -24.26% | -46.28% |
VRTX | 77.3B | 8.9B | -1.64% | 19.14% | 23.26 | 8.65 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -16.46% | 21.47% | -20.78 | 22.66 | 22.88% | -32.64% |
SRPT | 13.2B | 933.0M | 21.02% | 90.98% | -18.71 | 14.11 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -15.04% | 21.63% | 13.93 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.5B | 504.0K | -6.48% | 165.34% | -15.07 | 2.5K | -66.53% | -22.12% |
RARE | 2.8B | 363.3M | -7.03% | -36.05% | -3.99 | 7.77 | 3.39% | -55.81% |
BPMC | 2.7B | 204.0M | 2.71% | -22.88% | -4.84 | 13.22 | 13.30% | 13.44% |
MRTX | 2.5B | 12.4M | -10.70% | -44.17% | -3.35 | 199.44 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.6B | 191.8M | -7.72% | 90.19% | 24.49 | 8.55 | 43.59% | 60.82% |
MGNX | 429.6M | 93.0M | -0.16% | -22.78% | -2.25 | 4.62 | -19.83% | -30.37% |
CRBP | 24.0M | - | -31.83% | 665.59% | -0.57 | 19.11 | -77.61% | 7.22% |
CYTK | 3.5M | 94.6M | -15.04% | 9.81% | -0.01 | 0.04 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 6.5% | 933,013,000 | 876,047,000 | 835,184,000 | 765,786,000 | 701,887,000 |
S&GA Expenses | 10.4% | 451,421,000 | 408,998,000 | 365,338,000 | 283,369,000 | 282,660,000 |
Costs and Expenses | 4.1% | 1,469,214,000 | 1,411,228,000 | 1,273,468,000 | 1,160,512,000 | 1,161,597,000 |
EBITDA | 1.3% | -603,681,000 | -611,595,000 | -404,838,000 | -252,225,000 | - |
EBITDA Margin | 7.3% | -0.65 | -0.70 | -0.48 | -0.33 | - |
Earnings Before Taxes | 2.9% | -689,963,000 | -710,546,000 | -502,035,000 | -355,701,000 | -418,948,000 |
EBT Margin | 8.8% | -0.74 | -0.81 | -0.60 | -0.46 | - |
Interest Expenses | -22.7% | 44,418,000 | 57,495,000 | 55,949,000 | 55,949,000 | 55,949,000 |
Net Income | 1.8% | -703,488,000 | -716,225,000 | -506,631,000 | -356,555,000 | -418,780,000 |
Net Income Margin | 7.8% | -0.75 | -0.82 | -0.61 | -0.47 | - |
Free Cahsflow | -24.0% | -356,170,000 | -287,346,000 | -347,721,000 | -386,868,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -0.9% | 3,128 | 3,156 | 2,997 | 3,056 | 3,148 |
Current Assets | -2.6% | 2,558 | 2,626 | 2,469 | 2,531 | 2,604 |
Cash Equivalents | -6.9% | 967 | 1,039 | 869 | 1,234 | 2,116 |
Inventory | -7.8% | 204 | 221 | 208 | 199 | 186 |
Net PPE | -0.5% | 180 | 181 | 183 | 187 | 191 |
Liabilities | 0.7% | 2,743 | 2,725 | 2,270 | 2,199 | 2,220 |
Current Liabilities | 2.8% | 620 | 603 | 546 | 455 | 453 |
Shareholder's Equity | -10.7% | 385 | 431 | 726 | 857 | 928 |
Retained Earnings | -2.9% | -3,910 | -3,800 | -3,543 | -3,311 | -3,206 |
Additional Paid-In Capital | 1.5% | 4,297 | 4,235 | 4,272 | 4,169 | 4,135 |
Shares Outstanding | 0.2% | 88.00 | 88.00 | 88.00 | 87.00 | 87.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -24.0% | -325 | -262 | -321 | -363 | -443 |
Share Based Compensation | 9.8% | 233 | 212 | 189 | 115 | 114 |
Cashflow From Investing | 1.2% | -1,046 | -1,059 | -1,058 | -447 | 495 |
Cashflow From Financing | -69.8% | 233 | 771 | 560 | 564 | 562 |
89.2%
81.2%
39.2%
Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.
16.3%
39.0%
12.5%
13.4%
FIve years rolling returns for Sarepta Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -70.84 | -14,294,000 | 7,421,950 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 3,786 | 25,786 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -73.49 | -575,000 | 259,000 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | new | - | 1,000 | 1,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | unchanged | - | 1,662 | 11,662 | 0.01% |
2023-02-28 | Voya Investment Management LLC | added | 24.24 | 2,403,420 | 7,668,420 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | -56.00 | 1,944 | -% |
2023-02-24 | NATIXIS | reduced | -21.99 | -1,301,070 | 13,903,900 | 0.08% |
2023-02-21 | Empowered Funds, LLC | new | - | 3,010,790 | 3,010,790 | 0.20% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -21.2 | -379,000 | 3,318,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | sands capital management, llc | 2.5% | 2,151,378 | SC 13G/A | |
Feb 10, 2023 | janus henderson group plc | 6.9% | 6,028,016 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.15% | 8,033,264 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.3% | 5,557,234 | SC 13G/A | |
Feb 14, 2022 | sands capital management, llc | 6.16% | 5,364,627 | SC 13G | |
Feb 11, 2022 | janus henderson group plc | 8.3% | 7,245,862 | SC 13G | |
Feb 10, 2022 | vanguard group inc | 9.54% | 8,311,108 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 6.1% | 5,285,234 | SC 13G/A | |
Aug 10, 2021 | capital research global investors | 4.8% | 3,842,491 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.77 -98.82% | 3.92 -97.38% | 10.58 -92.93% | 23.14 -84.54% | 48.53 -67.58% |
Current Inflation | 1.61 -98.92% | 3.53 -97.64% | 9.30 -93.79% | 20.03 -86.62% | 41.62 -72.19% |
Very High Inflation | 1.42 -99.05% | 3.04 -97.97% | 7.78 -94.80% | 16.42 -89.03% | 33.66 -77.51% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-08 | Estepan Ian Michael | sold (taxes) | -113,973 | 153 | -744 | chief financial officer |
2023-03-08 | Brown Ryan Edward | sold (taxes) | -97,275 | 153 | -635 | svp, general counsel |
2023-03-08 | Arif Bilal | sold (taxes) | -48,101 | 153 | -314 | chief tech ops officer |
2023-03-08 | Rodino-Klapac Louise | sold (taxes) | -139,709 | 153 | -912 | head of r&d, cso |
2023-03-06 | Mayo Stephen | acquired | - | - | 1,523 | - |
2023-03-06 | Nicaise Claude | acquired | - | - | 1,523 | - |
2023-03-06 | Rodino-Klapac Louise | acquired | - | - | 4,500 | head of r&d, cso |
2023-03-06 | Wigzell Hans Lennart Rudolf | acquired | - | - | 1,523 | - |
2023-03-06 | Arif Bilal | acquired | - | - | 4,500 | chief tech ops officer |
2023-03-06 | Estepan Ian Michael | sold (taxes) | -215,378 | 157 | -1,370 | chief financial officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||
Revenues: | |||||
Products, net | $ 843,769 | $ 612,401 | $ 455,865 | ||
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | ||
Collaboration and other | $ 89,244 | $ 89,486 | $ 84,234 | ||
Total revenues | 933,013 | 701,887 | 540,099 | ||
Cost and expenses: | |||||
Cost of sales (excluding amortization of in-licensed rights) | 139,989 | 97,049 | 63,382 | ||
Research and development | 877,090 | 771,182 | 722,343 | ||
Selling, general and administrative | 451,421 | 282,660 | 317,875 | ||
Settlement and license charges | 0 | 10,000 | 0 | ||
Amortization of in-licensed rights | 714 | 706 | 662 | ||
Total cost and expenses | 1,469,214 | 1,161,597 | 1,104,262 | ||
Operating loss | (536,201) | (459,710) | (564,163) | ||
Other (loss) income, net: | |||||
Loss on debt extinguishment | (125,441) | 0 | 0 | ||
Gain (loss) on contingent consideration, net* | [1] | 6,700 | 7,200 | (45,000) | |
Gain from sale of Priority Review Voucher | 0 | 102,000 | 108,069 | ||
Other expense, net | (35,021) | (68,438) | (51,971) | ||
Total other (loss) income, net | (153,762) | 40,762 | 11,098 | ||
Loss before income tax (benefit) expense | (689,963) | (418,948) | (553,065) | ||
Income tax expense (benefit) | 13,525 | (168) | 1,063 | ||
Net loss | (703,488) | (418,780) | (554,128) | ||
Other comprehensive loss: | |||||
Unrealized losses on investments, net of tax | (1,644) | (23) | (47) | ||
Total other comprehensive loss | (1,644) | (23) | (47) | ||
Comprehensive loss | $ (705,132) | $ (418,803) | $ (554,175) | ||
Net loss per share - basic and diluted | $ (8.03) | $ (5.15) | $ (7.11) | ||
Net loss per share - basic and diluted | $ (8.03) | $ (5.15) | $ (7.11) | ||
Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 87,559,000 | 81,262,000 | 77,956,000 | ||
Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 87,559,000 | 81,262,000 | 77,956,000 | ||
|
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 966,777 | $ 2,115,869 |
Short-term investments | 1,022,597 | 0 |
Accounts receivable | 214,628 | 152,990 |
Inventory | 203,968 | 186,212 |
Other current assets | 149,891 | 149,028 |
Total current assets | 2,557,861 | 2,604,099 |
Property and equipment, net | 180,037 | 191,156 |
Intangible assets, net | 7,578 | 14,239 |
Right of use assets | 64,954 | 45,531 |
Other non-current assets | 317,936 | 292,949 |
Total assets | 3,128,366 | 3,147,974 |
Current liabilities: | ||
Accounts payable | 95,875 | 76,741 |
Accrued expenses | 418,996 | 271,697 |
Deferred revenue, current portion | 89,244 | 89,244 |
Other current liabilities | 15,489 | 15,051 |
Total current liabilities | 619,604 | 452,733 |
Long-term debt | 1,544,292 | 1,096,876 |
Lease liabilities, net of current portion | 57,578 | 41,512 |
Deferred revenue, net of current portion | 485,000 | 574,244 |
Contingent consideration | 36,900 | 43,600 |
Other non-current liabilities | 42 | 11,000 |
Total liabilities | 2,743,416 | 2,219,965 |
Commitments and contingencies (Note 21) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | 0 | 0 |
Common stock, $0.0001 par value, 198,000,000 shares authorized; 87,950,117 and 87,126,974 issued and outstanding at December 31, 2022 and 2021, respectively | 9 | 9 |
Additional paid-in capital | 4,296,841 | 4,134,768 |
Accumulated other comprehensive loss, net of tax | (1,664) | (20) |
Accumulated deficit | (3,910,236) | (3,206,748) |
Total stockholders’ equity | 384,950 | 928,009 |
Total liabilities and stockholders’ equity | $ 3,128,366 | $ 3,147,974 |